BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models

DNA damaging agents cause rapid shrinkage of tumors and form the basis of chemotherapy for sarcomas despite significant toxicities. Drugs having superior efficacy and wider therapeutic windows are needed to improve patient outcomes. We used cell proliferation and apoptosis assays in sarcoma cell lin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Ambati, Srikanth R., Shieh, Jae-Hung, Pera, Benet, Lopes, Eloisi Caldas, Chaudhry, Anisha, Wong, Elissa W.P., Saxena, Ashish, Su, Tsann-Long, Moore, Malcolm A.S.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5190008/
https://ncbi.nlm.nih.gov/pubmed/27248664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9657
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky